Cargando…

Chronic obstructive pulmonary disease and β‐blocker treatment in Asian patients with heart failure

AIMS: Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are increasingly frequent in Asia and commonly coexist in patients. However, the prevalence of COPD among Asian patients with HF and its impact on HF treatment are unclear. METHODS AND RESULTS: We compared clinical characteris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kubota, Yoshiaki, Tay, Wan Ting, Asai, Kuniya, Murai, Koji, Nakajima, Ikutaro, Hagiwara, Nobuhisa, Ikeda, Takanori, Kurita, Takashi, Teng, Tiew‐Hwa Katherine, Anand, Inder, Lam, Carolyn S.P., Shimizu, Wataru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880660/ https://www.ncbi.nlm.nih.gov/pubmed/29055972 http://dx.doi.org/10.1002/ehf2.12228

Ejemplares similares

Impact of beta‐blocker use on the long‐term outcomes of heart failure patients with chronic obstructive pulmonary disease
por: Kubota, Yoshiaki, et al.
Publicado: (2021)

Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease
por: Kubota, Yoshiaki, et al.
Publicado: (2015)

Prevalence and Prognostic Significance of Frailty in Asian Patients With Heart Failure: Insights From ASIAN-HF
por: Aung, Than, et al.
Publicado: (2021)

Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIAN‐HF Registry
por: Chyou, Janice Y., et al.
Publicado: (2021)

Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry
por: Tromp, Jasper, et al.
Publicado: (2018)

COPD advances in left ventricular diastolic dysfunction
por: Kubota, Yoshiaki, et al.
Publicado: (2016)

Correction: Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry
por: Tromp, Jasper, et al.
Publicado: (2018)

Patient‐reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence
por: Huang, Weiting, et al.
Publicado: (2020)

Prevalence, clinical correlates, and outcomes of anaemia in multi‐ethnic Asian patients with heart failure with reduced ejection fraction
por: Goh, Vera J., et al.
Publicado: (2018)

Polypill Eligibility for Patients with Heart Failure with Reduced Ejection Fraction in the ASIAN-HF Registry: A Cross-Sectional Analysis
por: Vijay, Aishwarya, et al.
Publicado: (2023)

Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN‐HF Registry
por: MacDonald, Michael R., et al.
Publicado: (2019)

Plaque Characteristics in Coronary Artery Disease Patients with Impaired Glucose Tolerance
por: Suzuki, Keishi, et al.
Publicado: (2016)

Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study
por: Chandramouli, Chanchal, et al.
Publicado: (2019)

Prognostic values of highly sensitive cardiac troponin T and B-type natriuretic peptide for clinical features in hypertrophic obstructive cardiomyopathy: a cross-sectional study
por: Nakamura, Shunichi, et al.
Publicado: (2014)

Effect of Empagliflozin in Preventing Progression of Renal Dysfunction in Diabetic Patients With Compensated Heart Failure　― Reply ―
por: Shirakabe, Akihiro, et al.
Publicado: (2021)

Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction
por: Tay, Wan Ting, et al.
Publicado: (2021)

Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction
por: Teramoto, Kanako, et al.
Publicado: (2022)

N‐terminal pro‐B‐type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure
por: Tromp, Jasper, et al.
Publicado: (2018)

Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta‐analysis
por: Danielson, Cecilia, et al.
Publicado: (2022)

Status of Medical Care and Management Requirements of Elderly Patients With Heart Failure in a Comprehensive Community Health System　― Survey of General Practitioners’ Views ―
por: Tsukada, Yayoi Tetsuou, et al.
Publicado: (2021)

Predictive Factors for Decreasing Left Ventricular Ejection Fraction and Progression to the Dilated Phase of Hypertrophic Cardiomyopathy
por: Ishihara, Kakeru, et al.
Publicado: (2023)

Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
por: Kubota, Yoshiaki, et al.
Publicado: (2022)

Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction
por: Yap, Jonathan, et al.
Publicado: (2019)

Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale
por: Kubota, Yoshiaki, et al.
Publicado: (2018)

An unusual toxicity with beta blocker and calcium channel blocker
por: Anand, Vijay, et al.
Publicado: (2015)

Enlarged right atrium predicts pacemaker implantation after atrial fibrillation ablation in patients with tachycardia-bradycardia syndrome()
por: Arai, Toshiki, et al.
Publicado: (2023)

Ethnic differences in atrial fibrillation among patients with heart failure in Asia
por: Tan, Eugene S.J., et al.
Publicado: (2020)

Patient-Reported Status and Heart Failure Outcomes in Asia by Sex, Ethnicity, and Socioeconomic Status
por: Lawson, Claire A., et al.
Publicado: (2023)

Relationship of maximum walking speed with peak oxygen uptake and anaerobic threshold in male patients with heart failure
por: Koen, Masahiro, et al.
Publicado: (2023)

Evaluation of myocardial glucose metabolism in hypertrophic cardiomyopathy using (18)F-fluorodeoxyglucose positron emission tomography
por: Aoyama, Rie, et al.
Publicado: (2017)

Practical applicability of landiolol, an ultra-short-acting β1-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction
por: Wada, Yuko, et al.
Publicado: (2016)

Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus
por: Hoshika, Yu, et al.
Publicado: (2021)

Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus
por: Mozawa, Kosuke, et al.
Publicado: (2021)

Brugada Syndrome as a Major Cause of Sudden Cardiac Death in Asians
por: Nakano, Yukiko, et al.
Publicado: (2022)

Worsening renal function definition is insufficient for evaluating acute renal failure in acute heart failure
por: Shirakabe, Akihiro, et al.
Publicado: (2018)

Worsening renal failure in patients with acute heart failure: the importance of cardiac biomarkers
por: Shirakabe, Akihiro, et al.
Publicado: (2019)

Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis
por: Jin, Xuanyi, et al.
Publicado: (2022)

Radiofrequency catheter ablation of the left ventricular epicardium as an electrophysiological substrate in a patient with idiopathic ventricular fibrillation associated with early repolarization
por: Nakajima, Ikutaro, et al.
Publicado: (2023)

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
por: Shimizu, Wataru, et al.
Publicado: (2020)

Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes
por: Nishida, Yayoi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7i97l2e940ihlp4be7km1fo74l